Clinical Report: Inflammatory Pathways and Therapeutic Innovations in Autism Spectrum Disorder

Overview

This report synthesizes evidence linking neuroinflammation to autism spectrum disorder (ASD) and proposes the Peripheral-to-Central Inflammatory Cascade-Amplification Model (PC-ICAM) as a framework for understanding and targeting therapeutic interventions. It highlights the need for multi-node, mechanism-matched interventions rather than relying on single anti-inflammatory strategies.

Background

ASD is a complex neurodevelopmental disorder with rising prevalence and significant impacts on individuals and healthcare systems. Understanding the underlying mechanisms, particularly the role of neuroinflammation, is crucial for developing effective treatments. Current diagnostic methods lack objective biomarkers, emphasizing the need for mechanistic insights to guide therapeutic strategies.

Data Highlights

Key Findings

• Neuroinflammation is linked to ASD risk, symptom development, and long-term outcomes.
• The PC-ICAM model outlines a cascade from peripheral immune perturbation to central nervous system amplification.
• Key inflammatory pathways involved include NF-κB, JAK/STAT, and MAPK/ERK.
• Candidate interventions target various inflammatory mediators and pathways, including IL-6/IL-17 signaling and glial modulation.
• Neuroinflammation can disrupt synaptic homeostasis and excitation-inhibition balance, impacting neurodevelopment.

Clinical Implications

Clinicians should consider the role of neuroinflammation in ASD when developing treatment plans. A multi-faceted approach targeting various inflammatory pathways may enhance therapeutic efficacy and address the complex nature of ASD.

Conclusion

The PC-ICAM model provides a structured understanding of neuroinflammation in ASD, highlighting the potential for targeted, mechanism-based interventions. Future research should focus on validating these therapeutic strategies.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Author(s)/Org, Source, Year -- Title
9. Cochrane Review on Atypical Antipsychotics
10. NICE Guidelines on Autism
11. AAP Guidance on Leucovorin Use
12. Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms | BMC Medicine | Springer Nature Link
13. Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology | BMC Pharmacology and Toxicology | Springer Nature Link
14. Efficacy of Antioxidant-Based Pharmacological Therapies in Autism Spectrum Disorder: A Systematic Review | Journal of Autism and Developmental Disorders | Springer Nature Link
15. Microbiota-based therapies as novel targets for autism spectrum disorder: A systematic review and meta-analysis - ScienceDirect
16. Accelerated intermittent theta burst stimulation targeting personalized fronto-parietal control network improves core symptoms of autism spectrum disorder: a double-blind, randomized controlled trial | Molecular Psychiatry
17. Frontiers | Microglia in autism spectrum disorder: heterogeneity, immunometabolism, and synapse-related pathways